Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthequity (HQY) Cash & Equivalents (2016 - 2026)

Healthequity has reported Cash & Equivalents over the past 14 years, most recently at $318.9 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 7.76% year-over-year to $318.9 million; the TTM value through Jan 2026 reached $318.9 million, up 7.76%, while the annual FY2026 figure was $318.9 million, 7.76% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $318.9 million at Healthequity, up from $309.3 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $404.0 million in Q1 2024 and troughed at $161.2 million in Q2 2022.
  • A 5-year average of $276.4 million and a median of $290.3 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: tumbled 78.11% in 2022 and later surged 64.14% in 2023.
  • Year by year, Cash & Equivalents stood at $210.2 million in 2022, then soared by 58.93% to $334.1 million in 2023, then fell by 3.56% to $322.2 million in 2024, then dropped by 4.01% to $309.3 million in 2025, then rose by 3.13% to $318.9 million in 2026.
  • Business Quant data shows Cash & Equivalents for HQY at $318.9 million in Q1 2026, $309.3 million in Q4 2025, and $304.5 million in Q3 2025.